PTC Therapeutics (PTCT) Stock Price, News & Analysis

Company Overview

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets. The company also commercializes Emflaza (deflazacort) for patients with Duchenne muscular dystrophy, expanding its portfolio in neuromuscular disease. PTC’s pipeline extends into areas such as central nervous system disorders and metabolic diseases, with programs advancing through clinical and preclinical stages to address rare forms of Rett syndrome, tyrosinemia and other genetic conditions.

Headquartered in South Plainfield, New Jersey, PTC operates a global network encompassing commercial, research and manufacturing facilities across North America, Europe and Asia. The company’s leadership team is led by Stuart W. Peltz, Ph.D., who has served as Chief Executive Officer since co-founding the business. Under his guidance, PTC has established strategic collaborations and regulatory approvals that bolster its presence in key international markets, reflecting a commitment to bringing innovative therapies to patients around the world.

Key Stats

• Today's Range: $64.57 to $73.72
• 50-Day Range: $67.65 to $89.57
• 52-Week Range: $43.17 to $90.87
• Volume: 4.33 million shs
• Average Volume: 1.48 million shs
• Market Capitalization: $5.64 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $95.75
• Consensus Rating: Moderate Buy

PTC Therapeutics Stock Analysis - MarketRank™

PTC Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 66th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 2 strong buy ratings, 9 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

PTC Therapeutics has a consensus price target of $95.75, representing about 39.7% upside from its current price of $68.52.

Amount of Analyst Coverage

PTC Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 419.51%

Earnings Growth

Earnings for PTC Therapeutics are expected to grow by 419.51% in the coming year, from $0.41 to $2.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PTC Therapeutics is -29.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PTC Therapeutics is -29.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

PTC Therapeutics has a PEG Ratio of 6.49. PEG Ratios above 1 indicate that a company could be overvalued.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.55% of the float of PTC Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

PTC Therapeutics has a short interest ratio ("days to cover") of 4.75.

Change versus previous month

Short interest in PTC Therapeutics has recently decreased by 43.21%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PTC Therapeutics does not currently pay a dividend.

Dividend Growth

PTC Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.93

News Sentiment

PTC Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for PTC Therapeutics this week, compared to 6 articles on an average week.

Search Interest

4 people have searched for PTCT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

1 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,347,994.00 in company stock.

Percentage Held by Insiders

5.50% of the stock of PTC Therapeutics is held by insiders.

Percentage Held by Institutions

PTC Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 7/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PTCT
• CIK: 1070081
• Web: www.ptcbio.com
• Phone: (908) 222-7000
• Fax: 908-222-7231
• Employees: 1,410
• Year Founded: 1998

Price Target and Rating

• Average Price Target for PTC Therapeutics: $95.75
• High Price Target: $130.00
• Low Price Target: $50.00
• Potential Upside/Downside: +40.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.79
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 165.88
• P/E Growth: 6.49
• Net Income: $682.64 million
• Net Margins: -22.58%
• Pretax Margin: -28.49%
• Return on Equity: -362.45%
• Return on Assets: -6.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.44
• Quick Ratio: 2.36

Sales & Book Value

• Annual Sales: $1.73 billion
• Price / Sales: 3.26
• Cash Flow: $8.01 per share
• Price / Cash Flow: 8.49
• Book Value: ($2.56) per share
• Price / Book: -26.57

Miscellaneous

• Outstanding Shares: 82,950,000
• Free Float: 78,387,000
• Market Cap: $5.64 billion
• Optionable: Optionable
• Beta: 0.53